Bevacizumab and Tocotrienol in Recurrent Platinum-Resistant Ovarian Cancer, and the Role of HOXA9 as a Prognostic Biomarker
Treatment was well tolerated in this heavily pretreated cohort of PR-ROC patients with expected poor prognostic outcomes, with a few individuals showing extraordinary response in terms of progression free survival. The study was not powered to reproduce evidence of potential of meth-HOXA9 as a prognostic biomarker in PR-ROC.
Authors
- Louise Faaborg (ORCID: https://orcid.org/0000-0002-9630-9648)
- R Andersen
- Elisabeth Emanuel Graae
- Lars Ulrik Fokdal
- Caroline Brenner Thomsen
Institutions
- Aarhus University Hospital (DK)
- Lillebaelt Hospital (DK)
Publication Details
- Journal
- Diseases
- Published
- 2026-03-12
- DOI
- https://doi.org/10.3390/diseases14030104
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Odense Universitetshospital